公开(公告)号：US20240360443A1

公开(公告)日：2024-10-31

申请号：US18609277

申请日：2024-03-19

Applicant: Dystrogen Gene Therapies Inc.

Inventor： Marta OLEJNICZAK ,  Anna KOTOWSKA-ZIMMER ,  Marianna PEWINSKA ,  Paul LEWICKI ,  Krzysztof SIEMIONOW

IPC: C12N15/113 ,  A61P25/28 ,  C12N15/86

CPC classification number: C12N15/113 ,  A61P25/28 ,  C12N15/86 ,  C12N2310/141 ,  C12N2310/531 ,  C12N2750/14143

Abstract: A nucleic acid molecule composed of a duplex and loop, in which one of the duplex strands, the guide strand, comprises a sequence chosen from SEQ ID NO. 1-4, and the other strand of the duplex, the passenger strand, is at least 80% complementary to the guide strand, wherein the nucleic acid molecule forms a hairpin structure in a cell.

公开(公告)号：US20240360164A1

公开(公告)日：2024-10-31

申请号：US18411480

申请日：2024-01-12

Applicant: Cyclerion Therapeutics, Inc.

Inventor： James Edward Sheppeck ,  Paul Allan Renhowe ,  Ara Mermerian ,  Timothy Claude Barden ,  Glen Robert Rennie ,  Rajesh R. Iyengar ,  Takashi Nakai

IPC: C07F9/6558 ,  A61P3/00 ,  A61P9/10 ,  A61P9/12 ,  A61P25/28

CPC classification number: C07F9/65583 ,  A61P3/00 ,  A61P9/10 ,  A61P9/12 ,  A61P25/28 ,  C07F9/65586

Abstract: The present patent application discloses the compounds according to Formula I shown below, or pharmaceutically acceptable salts thereof, wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.

公开(公告)号：US20240360127A1

公开(公告)日：2024-10-31

申请号：US18763210

申请日：2024-07-03

Applicant: Ventus Therapeutics U.S., Inc.

Inventor： Stéphane DORICH ,  Amandine CHEFSON

IPC: C07D471/04 ,  A61P25/28

CPC classification number: C07D471/04 ,  A61P25/28

Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.

公开(公告)号：US12128108B2

公开(公告)日：2024-10-29

申请号：US17979450

申请日：2022-11-02

Applicant: Aihol Corporation

Inventor： Szu-Yuan Lee ,  Ping-Shan Lai ,  Chih-An Lin

IPC: A61K47/61 ,  A61K31/565 ,  A61K31/566 ,  A61K31/568 ,  A61K31/573 ,  A61K47/54 ,  A61P25/28

CPC classification number: A61K47/61 ,  A61K31/565 ,  A61K31/566 ,  A61K31/568 ,  A61K31/573 ,  A61K47/542 ,  A61P25/28

Abstract: Disclosed herein is a method of using a hyaluronan conjugate, which includes a hyaluronic acid (HA), a sex hormone, and a linker for coupling one of the disaccharide units of the HA and the sex hormone. The hyaluronan conjugates are used in treating neurodegenerative diseases.

公开(公告)号：US12128031B2

公开(公告)日：2024-10-29

申请号：US18206559

申请日：2023-06-06

Applicant: HB Biotech, Inc.

Inventor： Alon Seifan

IPC: A61K31/4184 ,  A61K31/277 ,  A61K33/08 ,  A61K45/06 ,  A61P25/22 ,  A61P25/28

CPC classification number: A61K31/4184 ,  A61K31/277 ,  A61K33/08 ,  A61K45/06 ,  A61P25/22 ,  A61P25/28

Abstract: As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

公开(公告)号：US12128020B2

公开(公告)日：2024-10-29

申请号：US18591994

申请日：2024-02-29

Applicant: AXCESS GLOBAL SCIENCES, LLC

Inventor： Ryan Lowery ,  Jacob Wilson ,  Terry Lacore

IPC: A61K31/19 ,  A61K9/00 ,  A61K31/522 ,  A61P3/04 ,  A61P25/28

CPC classification number: A61K31/19 ,  A61K9/0053 ,  A61K31/522 ,  A61P3/04 ,  A61P25/28

Abstract: In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof.

公开(公告)号：US20240352106A1

公开(公告)日：2024-10-24

申请号：US18650019

申请日：2024-04-29

Applicant: The Board of Regents of The University of Texas System

Inventor： Nancy MONSON

IPC: C07K16/18 ,  A61P25/28 ,  C12N15/113

CPC classification number: C07K16/18 ,  A61P25/28 ,  C12N15/113 ,  C07K2317/21 ,  C07K2317/56 ,  C12N2310/11 ,  C12N2310/14

Abstract: The present disclosure in various aspects provides methods for making pharmaceutical compositions for treating neurodegenerative diseases (e.g., demyelinating diseases), such as but not limited to multiple sclerosis, neuromyelitis optica, and transverse myelitis. The pharmaceutical compositions impact specific antibody-mediated processes involved in the biology of neurodegenerative disease. In certain aspects, the disclosure provides pharmaceutical compositions for treating neurodegenerative disease, which are based on inhibiting the action of pathologic antibodies, or alternatively providing antibodies to stimulate neuroprotection or repair processes.

公开(公告)号：US20240351983A1

公开(公告)日：2024-10-24

申请号：US18758102

申请日：2024-06-28

Applicant: Gilgamesh Pharmaceuticals, Inc.

Inventor： Andrew Carry Kruegel

IPC: C07D209/16 ,  A61K31/4045 ,  A61P25/24 ,  A61P25/28

CPC classification number: C07D209/16 ,  A61K31/4045 ,  A61P25/24 ,  A61P25/28

Abstract: Methods of treating mood disorders with compounds disclosed herein. Also provided are pharmaceutical compositions that include those compounds.

公开(公告)号：US20240350598A1

公开(公告)日：2024-10-24

申请号：US18650535

申请日：2024-04-30

Applicant: AC Immune SA

Inventor： Emma Fiorini ,  Marija Vukicevic Verhille ,  Maria Pihlgren Bosch

IPC: A61K39/00 ,  A61K9/127 ,  A61K39/05 ,  A61K39/08 ,  A61K39/245 ,  A61K39/39 ,  A61P25/28 ,  C07K14/005

CPC classification number: A61K39/0007 ,  A61K9/127 ,  A61K39/0003 ,  A61K39/0005 ,  A61K39/05 ,  A61K39/08 ,  A61K39/245 ,  A61K39/39 ,  A61P25/28 ,  C07K14/005 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/58 ,  A61K2039/627 ,  A61K2039/645 ,  A61K2039/70 ,  C07K2319/33 ,  C07K2319/55 ,  C12N2710/16232 ,  C12N2710/16234 ,  C12N2760/16033

Abstract: A liposomal vaccine composition comprises a β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome. The vaccine composition also comprises a peptide comprising a universal T-cell epitope encapsulated within the liposome. The vaccine composition also comprises an adjuvant, which may form part of the liposome and may be displayed at least in part on the surface of the liposome. These vaccine compositions are used for treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition or a condition characterised by, or associated with, loss of cognitive memory capacity in a subject. The vaccine compositions may be provided as a kit. Related methods of producing a liposomal vaccine composition are also provided.

公开(公告)号：US20240349771A1

公开(公告)日：2024-10-24

申请号：US18637077

申请日：2024-04-16

Applicant: SOCIETE DES PRODUITS NESTLE S.A.

Inventor： Nora Schneider ,  Jonas Hauser ,  Sean Deoni ,  Tamas Bartfai ,  Jonathan O'Regan

IPC: A23L33/00 ,  A23L33/12 ,  A23L33/15 ,  A23L33/16 ,  A24B15/38 ,  A61K9/00 ,  A61K31/14 ,  A61K31/202 ,  A61K31/519 ,  A61K31/661 ,  A61K31/70 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K45/06 ,  A61P25/28

CPC classification number: A23L33/40 ,  A23L33/12 ,  A23L33/15 ,  A23L33/16 ,  A23L33/30 ,  A24B15/38 ,  A61K9/0095 ,  A61K31/14 ,  A61K31/202 ,  A61K31/519 ,  A61K31/661 ,  A61K31/70 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K45/06 ,  A61P25/28 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/1564 ,  A23V2250/1578 ,  A23V2250/1588 ,  A23V2250/1592 ,  A23V2250/161 ,  A23V2250/1618 ,  A23V2250/1642 ,  A23V2250/1846 ,  A23V2250/185 ,  A23V2250/1852 ,  A23V2250/1862 ,  A23V2250/1886 ,  A23V2250/5424 ,  A23V2250/7056 ,  A23V2250/706

Abstract: A synthetic nutritional composition containing a phospholipid and/or a metabolic precursor and/or metabolite thereof for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential, and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.